Esophageal Cancer: Our Clinical Trials

In addition to providing excellent care, Memorial Sloan-Kettering is constantly working to improve treatment for esophageal cancer. Our clinical trials enable us to investigate a variety of new approaches for the diagnosis and treatment of esophageal cancer.

Choosing Memorial Sloan-Kettering for your cancer care may offer you access to new therapies that are not widely available elsewhere. Our clinical research team can help determine whether a clinical trial would be right for you, and will work with your esophageal cancer disease management team to ensure that you receive the best possible care. 

Below is a list of clinical trials  that are currently enrolling patients with esophageal cancer at Memorial Sloan-Kettering.

Showing 12 trials
Title Investigator
A Phase II Study of Afatinib (BIBW 2992) in Patients with Advanced HER2-Positive Esophagogastric Cancer Refractory to Trastuzumab
[Protocol 11-166]
Janjigian, Yelena, MD
A Phase II Study of FOLFOX plus Regorafenib in Patients with Inoperable or Metastatic Esophageal and/or Stomach Cancer
[Protocol 13-080]
Janjigian, Yelena, MD
A Phase II Study of Ipilimumab versus Standard Chemotherapy after Initial Therapy in Patients with Inoperable or Advanced Gastric or Gastroesophageal Cancer
[Protocol 12-277]
Ku, Geoffrey, MD
A Phase II Study of Neratinib in Patients with Solid Tumors Containing Mutated HER2
[Protocol 13-140]
Solit, David, MD
A Phase II Study of PET Scan-Directed Combined Modality Therapy for Esophageal Cancer
[Protocol 12-011]
Ilson, David, MD
A Phase II Study of SNX-5422 in Patients with Select Advanced HER2 Cancers
[Protocol 13-112]
Voss, Martin, MD
A Phase III Study Evaluating the Addition of Trastuzumab to Standard Therapy for HER2-Positive Esophageal Cancers
[Protocol 12-094]
Wu, Abraham, MD
A Phase III Study of Standard Chemotherapy with and without Rilotumumab as Initial Treatment in Patients with Metastatic or Inoperable Gastric/Esophageal Cancer
[Protocol 13-091]
Ilson, David, MD
A Pilot Study to Identify Patient Factors Impacting Adherence to Oral Chemotherapy
[Protocol 11-194]
Ginex, Pamela, RN, EDD
A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Cancer
[Protocol 11-037]
Rizk, Nabil, MD
A Prospective Study to Determine if Variations in Tissue Oxygenation Are Associated with Leak Rates after Esophagectomy
[Protocol 11-192]
Rizk, Nabil, MD
Quality of Life Outcomes Following Minimally Invasive versus Open Esophagectomy for Esophageal Cancer
[Protocol 12-003]
Sarkaria, Inderpal, MD